Trial
NCT03600805
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
Regeneron Pharmaceuticals
Condition
Giant Cell Arteritis
Intervention
Sarilumab SAR153191
Why stopped
Protracted recruitment timeline exacerbated by COVID-19 pandemic
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-28